---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020826"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:46:49.383620+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PepGen Q1 2023 net loss $16.3M; cash $165.4M; pipeline milestones on track

## Summary
- Net loss of $16.3M for Q1 2023 vs $18.2M in Q1 2022; R&D expense $14.4M, G&A $3.7M.
- Cash, cash equivalents, and investments of $165.4M as of March 31, 2023; runway into early 2025.
- Phase 2 CONNECT1-EDO51 (open-label) for DMD expected to start in Canada H1 2023.
- Phase 2 CONNECT2-EDO51 (randomized, placebo-controlled) multinational study expected H2 2023.
- Phase 1 FREEDOM-DM1 for myotonic dystrophy type 1 expected to start H1 2023.

## SEC filing metadata
- accession: 0000950170-23-020826
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/0000950170-23-020826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/pepg-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020826
- JSON: https://secwatch.observer/filing/0000950170-23-020826.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020826.txt

## Key facts
- Earnings Releases
  PepGen Inc. reported the quarter ended March 31, 2023 results: net income $16.3 million.
  - Period: the quarter ended March 31, 2023
  - Net income: $16.3 million
  - Result: reported results
  source text: Net loss was $16.3 million for the three months ended March 31, 2023, compared to $18.2 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/0000950170-23-020826-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.